Table 1

Clinical trials of COVID-19 vaccines involving children*

NCT number NCT04551547
SSinovac Research and Development
EA3–17 years
NCT number NCT04471519
SBharat Biotech International
EA12–65 years
NCT number NCT04683484
SNanogen Pharmaceutical Biotechnology Joint Stock
EA12–75 years
NCT number NCT04566770
SCanSino Biologics
EA6 years and older
NCT number NCT04535453 (Postponed. See text)†
EudraCT number 2020-002584-63 (children not eligible in EU countries)
SJanssen Vaccines & Prevention (subsidiary of Johnson & Johnson)
EA12 years and older
18 years and older (until 3 December 2020)
PCBrazil, Canada, Germany, Netherlands, Spain, UK, USA
EudraCT number (2021) 2020-005720-11
SJanssen Vaccines & Prevention
EAFrom birth to 17 years; 18–55 years
PCSites planned: Argentina, Australia, Brazil, Canada, Colombia, Finland, Italy, Mexico, Poland, South Africa, Spain, Sweden, Turkey, UK, USA
NCT number NCT04400838
EudraCT number 2020-001228-32 (UK—only adults)
S/CUniversity of Oxford/AstraZeneca
EA18 years and older (participants aged 5–12 no longer eligible)
5–12 years; 18 years and older (until early December 2020)
ISRCTN (2021) ISRCTN15638344 (Postponed. See text)‡
S/CUniversity of Oxford/National Institute for Health Research (UK); AstraZeneca
EA6–17 years
NCT number NCT04299724
SShenzhen Geno-Immune Medical Institute
EA6 months to 80 years
NCT number NCT04276896
SShenzhen Geno-Immune Medical Institute
EA6 months to 80 years
NCT number NCT04368728
EudraCT number 2020-002641-42 (children not eligible in the EU)
EA12 years and older
16 years and older (from 25 September 2020 to 13 October 2020); 18 years (until 24 September 2020)
PCArgentina, Brazil, Germany, South Africa, Turkey, USA
NCT number (2021) NCT04713553
EA12–50 years
18–55 years (until 8 February 2021)
NCT number (2021) NCT04816643
EA6 months to 11 years
NCT number NCT04649151
EA12–17 years
NCT number (2021) NCT04796896
EA6 months to 11 years
NCT number (2021) NCT04863638
SChina National Biotec Group
EA3 years and older
NCT number (2021) NCT04800133
SThe University of Hong Kong
EA11 years and older
PCHong Kong Special Administrative Region of China
NCT number (2021) NCT04611802
EA12 years and older
18 years and older (until 26 April 2021)
PCMexico, USA (paediatric extension not applicable to Puerto Rico)
NCT number (2021) NCT04773067
SUnited Biomedical, Asia
EA12–85 years
  • Data current as of 1 May 2021.

  • *Created by the authors. Data sources: database (; EU Clinical Trials Register-EudraCT database (; and ISRCTN registry ( The search terms were ‘vaccine’ and ‘vaccination’, combined with ‘COVID-19’ and ‘SARS-CoV-2’. In the ISRCTN registry database, the search term used was ‘infections and infestations’. The lists of projects obtained were refined in order to exclude passive immunity strategies (convalescent plasma and monoclonal antibodies) and treatments with substances of chemical origin, as well as other activities, such as vaccine-promoting initiatives. The searches were conducted twice: on 1 January 2021 and 1 May 2021. The criteria followed, in the order of presentation of the studies listed in this table, are as follows: in the first instance, the degree of technological innovation (from inactivated vaccines to messenger RNA (mRNA)-based ones, with no intention of establishing any comparative ranking of vaccines within the same class); in the second instance, chronological order (2020, then 2021), except when the same sponsor had already registered a trial in children during 2020, in which case the 2021 trial is listed immediately below that sponsor’s earlier trial.

  • †Suspended from 16 April 2021 to 8 July 2021, according to the history of changes at the registry. From 9 July to 28 September 2021: active, not recruiting.

  • ‡Ongoing, not currently recruiting.

  • EA, eligible ages; EU, European Union; EudraCT number, EU Clinical Trials identifier; ISRCTN, International Standard Randomized Controlled Trial Number; NCT number, identifier; PC, participating countries; S, sponsor; S/C, sponsor/collaborators.